Antithrombin activation and designing novel heparin mimics

Chemistry and Biology of Heparin and Heparan Sulfate

Volumn , Issue , 2005, Pages 483-512

  Desai, Umesh R ^a  

^a Institute for Structural Biology and Drug Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882540439     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008044859-6/50018-6     Document Type: Chapter

References (108)

1. Franco RF, Reitsma PH Genetic risk factors of venous thrombosis. Hum Genet 2001, 109:369-384.
2. van Boven HH, Lane DA Antithrombin and its inherited deficiency states. Semin Hematol 1997, 34:188-204.
3. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997, 77:197-211.
4. Lane DA, Kunz G, Olds RJ, Thein SL Molecular genetics of antithrombin deficiency. Blood Rev 1996, 10:59-74.
5. Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, Takeda N, Ito M, Yamamoto K, Matsushita T, Kusugami K, Muramatsu T, Saito H Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000, 106:873-878.
6. Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T, Kadomatsu K, Nishimura M, Muramatsu T, Saito H Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002, 99:2455-2458.
7. Levy JH, Weisinger A, Ziomek CA, Echelard Y Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 2001, 27:405-416.
8. Gettins PGW, Patston PA, Olson ST Serpins: Structure, Function and Biology 1996, R G Landes Company, New York.
9. Gettins PGW Serpin structure, mechanism and function. Chem Rev 2002, 102:4751-4803.
10. Huntington JA, Read RJ, Carrell RW Structure of a serpin - protease complex shows inhibition by deformation. Nature 2000, 407:923-926.
11. Björk I, Olson ST Antithrombin: a bloody important serpin. Chemistry and Biology of Serpins 1997, 17-33. Plenum Press, New York. F.C. Church (Ed.).
12. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hol WGJ The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1994, 1:48-54.
13. Carrell RW, Stein PE, Fermi G, Wardell MR Biological implications of a 3 structure of dimeric antithrombin. Structure 1994, 2:257-270.
14. Skinner R, Abrahams J-P, Whisstock JC, Lesk AM, Carrell RW, Wardell MR The 2.6 structure of antithrombin indicates a conformational change at the heparin-binding site. J Mol Biol 1997, 266:601-609.
15. Baglin T, Carrell RW, Church FC, Esmon CT, Huntington JA Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 2002, 99:11079-11084.
16. Pike RN, Potempa J, Skinner R, Fitton HL, McGraw WT, Travis J, Owen M, Jin L, Carrell RW Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem 1997, 272:19652-19655.
17. Jairajpuri MA, Lu A, Bock SC Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition. J Biol Chem 2002, 277:24460-24465.
18. Chuang Y-J, Swanson R, Raja SM, Bock SC, Olson ST The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation. Biochemistry 2001, 40:6670-6679.
19. Chuang Y-J, Gettins PGW, Olson ST Importance of the P2 glycine of anti-thrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly ~ Pro mutation. J Biol Chem 1999, 274:28142-28149.
20. Olson ST, Chuang Y-J Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 2002, 12:331-338.
21. Olson ST, Björk I Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J Biol Chem 1991, 266:6353-6364.
22. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992, 267:12528-12538.
23. Bedsted T, Swanson R, Chuang Y-J, Bock PE, Björk I, Olson ST Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry 2003, 42:8143-8152.
24. Olson ST, Swanson R, Raub-Segall E, Bedsted T, Sadri M, Petitou M, Herault JP, Herbert JM, Björk I Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparins. Thromb Haemost 2004, 92:929-939.
25. Linhardt RJ, Loganathan D Heparin, heparinoids and heparin oligosaccharides: structure and biological activities. Biomimetic Polymers 1990, 135-173. Plenum Press, New York. C.G. Gebelein (Ed.).
26. Sasisekharan R, Venkataraman G Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 2000, 4:626-631.
27. Rabenstein DL Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002, 19:312-331.
28. Lindahl U, Backström G, Thunberg L, Leder IG Evidence for a 3-O-sulfated d-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980, 77:6551-6555.
29. Atha DH, Stephens AW, Rimon A, Rosenberg RD Sequence variation in heparin octasaccharides with high affinity from antithrombin III. Biochemistry 1984, 23:5801-5812.
30. Lindahl U, Thunberg L, Backström G, Riesenfeld J, Nordling K, Björk I Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 1984, 259:12368-12376.
31. Atha DH, Lormeau J-C, Petitou M, Rosenberg RD, Choay J Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 1985, 24:6723-6729.
32. van Boeckel CAA, Grootenhuis PDJ, Visser A A mechanism for heparin induced potentiation of antithrombin III. Nat Struct Biol 1994, 1:423-425.
33. Jin L, Abrahams J-P, Skinner R, Petitou M, Pike RN, Carrell RW The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997, 94:14683-14688.
34. Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW, Lesk AM Conformational changes in serpins: II. The mechanism of activation of anti-thrombin by heparin. J Mol Biol 2000, 301:1287-1305.
35. Meagher JL, Olson ST, Gettins PGW Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J Biol Chem 2000, 275:2698-2704.
36. Belzar KJ, Zhou A, Carrell RW, Gettins PGW, Huntington JA Helix D elongation and allosteric activation of antithrombin. J Biol Chem 2002, 277:8551-8558.
37. Huntington JA, Olson ST, Fan B, Gettins PGW Mechanism of heparin activation of antithrombin: Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry 1996, 35:8495-8503.
38. Futamura A, Gettins PGW Serine 380 (P14) --+ glutamate mutation activates antithrombin as an inhibitor of factor Xa. J Biol Chem 2000, 275:4092-4098.
39. Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PGW, Carrell RW The conformational activation of antithrombin: a 2.85 structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem 2000, 275:15377-15383.
40. Gettins PGW, Fan B, Crews BC, Turko IV Transmission of conformational change from the heparin binding site to the reactive center of antithrombin. Biochemistry 1993, 32:8385-8389.
41. Chuang Y-J, Swanson R, Raja SM, Olson ST Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 2001, 276:14961-14971.
42. Izaguirre G, Zhang W, Swanson R, Bedsted T, Olson ST Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J Biol Chem 2003, 278:51433-51440.
43. Huntington JA Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003, 1:1535-1549.
44. Manithody C, Yang L, Rezaie AR Role of basic residues of the autolysis loop in the catalytic function of factor Xa. Biochemistry 2002, 41:6780-6788.
45. Rezaie AR, Yang L, Manithody C Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin. Biochemistry 2004, 43:2898-2905.
46. Yang L, Manithody C, Rezaie AR Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. Blood 2004, 104:1753-1759.
47. Hermans JM, Stone SR Interaction of activated protein C with serpins. Biochem J 1993, 295:239-245.
48. Olson ST, Halvorson HR, Björk I Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem 1991, 266:6342-6352.
49. Duchaussoy P, Jaurand G, Driguez P-A, Lederman I, Ceccato M-L, Gourvenec F, Strassel J-M, Sizun P, Petitou M, Herbert J-M Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition. Carbohydr Res 1999, 317:85-99.
50. Petitou M, Herault J-P, Bernat A, Driguez P-A, Duchaussoy P, Lormeau J-C, Herbert J-M Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999, 398:417-422.
51. Rezaie AR Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. J Biol Chem 1998, 273:16824-16827.
52. Rezaie AR, Olson ST Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa binding complex. Demonstration by rapid kinetics studies. Biochemistry 2000, 39:12083-12090.
53. Herault JP, Gaich C, Bono F, Driguez PA, Duchaussoy P, Petitou M, Herbert JM The structure of synthetic oligosaccharides in relation to factor IXa inhibition. Thromb Haemost 2002, 88:432-435.
54. Rezaie AR Heparin-binding exosite of factor Xa. Trends Cardiovasc Med 2000, 10:333-338.
55. Whinna HC, Lesesky EB, Monroe DM, High KA, Larson PJ, Church FC Role of the ~/-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. J Thromb Haemost 2004, 2:1127-1134.
56. Desai UR, Swanson RS, Bock SC, Björk I, Olson ST The role of arginine 129 in heparin binding and activation of antithrombin. J Biol Chem 2000, 275:18976-18984.
57. Schedin-Weiss S, Desai UR, Bock SC, Gettins PGW, Björk I, Olson ST The importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry 2002, 41:4779-4788.
58. Arocas V, Bock SC, Raja S, Olson ST, Björk I Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001, 276:43809-43817.
59. Schedin-Weiss S, Arocas V, Bock SC, Olson ST, Björk I Specificity of the basic side chains of Lys114, Lys125 and Arg129 of antithrombin in heparin binding. Biochemistry 2002, 41:12369-12376.
60. Arocas V, Bock SC, Olson ST, Bjork I The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry 1999, 38:10196-10204.
61. Schedin-Weiss S, Desai UR, Bock SC, Olson ST, Björk I Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change. Biochemistry 2004, 43:675-683.
62. Monien BH, Krishnasamy C, Olson ST, Desai UR Importance of tryptophan 49 of antithrombin in heparin binding and conformational activation. Biochemistry 2005, 44:11660-11668.
63. Arocas V, Turk B, Bock SC, Olson ST, Björk I The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139. Biochemistry 2000, 39:8512-8518.
64. Meagher JL, Huntington JA, Gettins PGW Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. J Biol Chem 1996, 271:29353-29358.
65. Li W, Johnson DJD, Esmon CT, Huntington JA Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004, 11:857-862.
66. Dementiev A, Petitou M, Herbert J-M, Gettins PGW The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat Struct Mol Biol 2004, 11:863-867.
67. Streusand VJ, Björk I, Gettins PG, Petitou M, Olson ST Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. Role of the antithrombin binding pentasaccharide in heparin rate enhancement. J Biol Chem 1995, 270:9043-9051.
68. Rezaie AR Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem 2000, 275:3320-3327.
69. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J The refined 1.9 crystal structure of human α-thrombin. Interaction with d-Phe-Pro-Arg-chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989, 8:3467-3475.
70. Gan ZR, Li Y, Chen Z, Lewis SD, Shafer JA Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem 1994, 269:1301-1305.
71. Sheehan JP, Sadler JE Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA 1994, 91:5518-5522.
72. Tsiang M, Jain AK, Gibbs CS Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J Biol Chem 1997, 272:12024-12029.
73. Carter WJ, Cama E, Huntington JA Crystal structure of thrombin bound to heparin. J Biol Chem 2005, 280:2745-2749.
74. Desai UR, Petitou M, Björk I, Olson ST Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem 1998, 273:7478-7487.
75. Desai UR, Petitou M, Björk I, Olson ST Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites. Biochemistry 1998, 37:13033-13041.
76. Desai UR, Gunnarsson G Hydropathic interaction analysis of sequence-specific heparin pentasaccharide binding to antithrombin. Med Chem Res 1999, 9:643-655.
77. Olson ST, Srinivasan KR, Björk I, Shore JD Binding of high affinity heparin to antithrombin III: stopped flow kinetic studies of the binding interaction. J Biol Chem 1981, 256:11073-11079.
78. Capila I, Linhardt RJ Heparin-protein interactions. Angew Chem Int Ed 2002, 41:390-412.
79. Fareed J, Hoppensteadt DA, Bick RL An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000, 26(Suppl 1):5-21.
80. Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 2000, 97:10365-10370.
81. Islam T, Butler M, Sikkander SA, Toida T, Linhardt RJ Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Carbohydr Res 2002, 337:2239-2243.
82. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983, 116:492-499.
83. Cheng JWM Fondaparinux: a new antithrombotic agent. Clin Ther 2002, 24:1757-1769.
84. Samama M-M, Gerotziafas GT Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003, 109:1-11.
85. Tran AH, Lee G Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Ann Pharmacother 2003, 37:1632-1643.
86. Bauer KA New pentasaccharides for prophylaxis of deep vein thrombosis. Chest 2003, 124:364S-370S.
87. Orgueira HA, Bartolozzi A, Schell P, Litjens RE, Palmacci ER, Seeberger PH Modular synthesis of heparin oligosaccharides. Chemistry 2003, 9:140-169.
88. Desai UR New antithrombin-based anticoagulants. Med Res Rev 2004, 24:151-184.
89. Petitou M, van Boeckel CAA A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem Int Ed 2004, 43:3118-3133.
90. van Boeckel CAA, Petitou M The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed 1993, 32:1671-1818.
91. Petitou M, Hérault JP, Lormeau JC, Helmboldt A, Mallet J-M, Sinaÿ P, Herbert J-M Introducing a C-interglycosidic bond in a biologically active pentasaccharide hardly affects its biological properties. Bioorg Med Chem 1998, 6:1509-1516.
92. Kuberan B, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat Biotech 2003, 21:1343-1346.
93. Kuberan B, Beeler DL, Lawrence R, Lech M, Rosenberg RD Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin. J Am Chem Soc 2003, 125:12424-12425.
94. Kuberan B, Beeler DL, Lech M, Wu ZL, Rosenberg RD Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem 2003, 278:52613-52621.
95. Lindahl U, Li JP, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emeis J, Roberts I, Taylor C, Oreste P, Zoppetti G, Naggi A, Torri G, Casu B Generation of "eoheparin" from E. coli K5 capsular polysaccharide. J Med Chem 2005, 48:349-352.
96. Grootenhuis PDJ, van Boeckel CAA Constructing a molecular model of the interaction between antithrombin III and a potent heparin analogue. J Am Chem Soc 1991, 113:2743-2747.
97. Duchaussoy P, Jaurand G, Driquez P-A, Lederman I, Gourvenec F, Strassel J-M, Sizun P, Petitou M, Herbert J-M Identification of a hexasac-charide sequence able to inhibit thrombin and suitable for 'polymerisation'. Carbohydr Res 1999, 317:63-84.
98. Duchaussoy P, Jaurand G, Driquez P-A, Lederman I, Ceccato M-L, Gourvenec F, Strassel J-M, Sizun P, Petitou M, Herbert J-M Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition. Carbohydr Res 1999, 317:85-99.
99. Dreef-Tromp CM, Basten JEM, Broekhoven MA, van Dinther TG, Petitou M, van Boeckel CAA Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers. Bioorg Med Chem Lett 1998, 8:2081-2086.
100. Petitou M, Driguez PA, Duchaussoy P, Hérault J-P, Lormeau J-C, Herbert J-M Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics. Bioorg Med Chem Lett 1999, 9:1161-1166.
101. Sinaÿ P Sugars slide into heparin activity. Nature 1999, 398:377-378.
102. Buijsman RC, Basten JE, Dreef-Tromp CM, van der Marel GA, van Boeckel CAA, van Boom JH Synthesis of heparin-like antithrombotics having perphosphorylated thrombin binding domains. Bioorg Med Chem 1999, 7:1881-1890.
103. Gunnarsson GT, Desai UR Designing small, non-sugar activators of antithrombin using hydropathic interaction analyses. J Med Chem 2002, 45:1233-1243.
104. Gunnarsson GT, Desai UR Interaction of sulfated flavanoids with antithrombin: lessons on the design of organic activators. J Med Chem 2002, 45:4460-4470.
105. Desai UR, Gunnarsson GT Hydropathic interaction analysis of the sequence-specific heparin pentasaccharide binding to antithrombin. Med Chem Res 1999, 9:643-655.
106. Gunnarsson GT, Desai UR Exploring new non-sugar sulfated molecules as activators of antithrombin. Bioorg Med Chem Lett 2003, 13:579-583.
107. Gunnarsson GT, Riaz M, Adams J, Desai UR Synthesis of per-sulfated flavonoids using 2,2,2-trichloro ethyl protecting group and their factor Xa inhibition potential. Bioorg Med Chem 2005, 13:1783-1789.
108. Monien BH, Desai UR Antithrombin activation by nonsulfated, non-polysaccharide organic polymer. J Med Chem 2005, 48:1269-1273.